Hernández-Martin J, Romá E, Salavert M, Doménech L, Poveda J L
Servicio de Farmacia, Hospital Universitario La Fe, Avda. Campanar No. 21, 46009 Valencia, Spain.
Rev Esp Quimioter. 2006 Sep;19(3):231-46.
Cefditoren pivoxil, a new-third generation cephalosporin antibiotic that has recently been granted approval in Spain, shows important activity over a large part of the pathogens causing skin, soft tissue and respiratory tract infections, including Gram-negative and Gram-positive bacteria. Cefditoren has also been shown to be stable against hydrolysis by many common beta-lactamases. Data from in vitro studies and clinical trials show this antibiotic as an oral formulation with an intrinsic activity against Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae equivalent to that of other third-generation cephalosporins administered via parenteral, like cefotaxime or ceftriaxone, thereby placing its maximal benefits mainly in the treatment of ambulatory infections. This paper reviews the main characteristics of cefditoren pivoxil (spectrum of activity, chemical structure, mechanism of action, pharmacokinetics, adverse effects and clinical efficacy) and attempts to find its place in current antibiotic therapeutics.
头孢妥仑匹酯是一种新型第三代头孢菌素抗生素，最近在西班牙获得批准，对引起皮肤、软组织和呼吸道感染的大部分病原体具有重要活性，包括革兰氏阴性菌和革兰氏阳性菌。头孢妥仑也已被证明对许多常见的β-内酰胺酶的水解作用稳定。体外研究和临床试验的数据表明，这种抗生素作为口服制剂，对流感嗜血杆菌、卡他莫拉菌和肺炎链球菌的内在活性与其他通过胃肠外给药的第三代头孢菌素（如头孢噻肟或头孢曲松）相当，因此其最大益处主要在于治疗门诊感染。本文综述了头孢妥仑匹酯的主要特性（活性谱、化学结构、作用机制、药代动力学、不良反应和临床疗效），并试图确定其在当前抗生素治疗中的地位。
